Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma | Blood Cancer Journal
The Lancet on X: "NEW—First large randomised phase 3 trial (BOSTON) finds regimen of selinexor, bortezomib & dexamethasone was associated with significant increase in progression-free survival vs bortezomib & dexamethasone in patients
British Journal of Haematology | Wiley Online Library
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma | NEJM
Phase I/II Trial of Panobinostat with Lenalidomide/Bortezomib/ Dexamethasone for Transplant-Eligible Patients with Newly Diagnosed MM | Research To Practice
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. - Abstract - Europe PMC
Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma | Haematologica
DREAMM Clinical Trial Program
Newly Diagnosed: D + VTD Treatment | DARZALEX® IV (daratumumab)
BOSTON trial (SVd) Update at ASCO 2020 | Int Myeloma Fn
Phase II study of bortezomib–dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma | Haematologica
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial - The Lancet
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study - ScienceDirect
Relapsed: D + VD Treatment | DARZALEX® IV (daratumumab)
![PDF] Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/2f0ca3b1a7ecfca0a8a6fce95c955879f5ec3e35/9-Table3-1.png "PDF] Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. | Semantic Scholar")
PDF] Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. | Semantic Scholar
VisualAbstract Panobinostat, lenalidomide, bortezomib, and dexamethasone was well-tolerated and showed potential in treating relapsed/refractory multiple myeloma | 2 Minute Medicine
British Journal of Haematology | Wiley Online Library
Bortezomib, thalidomide and dexamethasone protocol (VTD). | Download Scientific Diagram
Changes in hemoglobin and IgA levels. BDR: bortezomib, dexamethasone,... | Download Scientific Diagram
Cancers | Free Full-Text | Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
Adding daratumumab to bortezomib-dexamethasone improves survival in myeloma patients - BJH
A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD - CDCN
Short‑course bortezomib‑based retreatment for patients with multiple myeloma who had received bortezomib‑thalidomide‑dexamethasone (VTD) as an initial therapy: A single‑center case series
Pomalidomide, Bortezomib, and Dexamethasone (PVd) for Chinese Multiple Myeloma Patients at First Relapse - ScienceDirect
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
